RevBio, Inc.

RevBio, Inc. is a regenerative medicine company developing TETRANITE®, a next‑generation bone adhesive that can be injected into fractures and implant sites to provide immediate, durable fixation while promoting natural bone remodeling. Drawing on a unique biomimetic chemistry derived from the sandcastle worm, TETRANITE has demonstrated superior curing speed, strength, resorption rate, and wet‑field adhesion in 150 patients across seven FDA‑approved trials, and it is protected by a comprehensive global patent portfolio through 2042. The company is positioned to receive a De Novo classification by Q3 2027, enabling rapid commercialization in a $10 billion neurosurgical, orthopedic, and dental market. RevBio’s culture blends rigorous scientific innovation with a mission to replace invasive metal hardware with a safer, more effective regenerative solution.